Your browser doesn't support javascript.
loading
Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021.
Ireland, Georgina; Whitaker, Heather; Ladhani, Shamez N; Baawuah, Frances; Subbarao, Sathyvani; Linley, Ezra; Warrener, Lenesha; O'Brien, Michelle; Whillock, Corinne; Martin, Oliver; Moss, Paul; Ramsay, Mary E; Amirthalingam, Gayatri; Brown, Kevin E.
Afiliación
  • Ireland G; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Whitaker H; Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom.
  • Ladhani SN; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Baawuah F; Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.
  • Subbarao S; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Linley E; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Warrener L; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • O'Brien M; Sero-Epidemiology Unit, UK Health Security Agency, Manchester, United Kingdom.
  • Whillock C; Virus Reference Department, UK Health Security Agency, London, United Kingdom.
  • Martin O; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Moss P; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Ramsay ME; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Amirthalingam G; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
  • Brown KE; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Euro Surveill ; 27(1)2022 01.
Article en En | MEDLINE | ID: mdl-34991777
Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2-4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2-4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido